Pipeline
 |
 |
 |
BB3 (HGF mimetic) |
Acute:
|
 |
Chronic:
|
|
|
 |
||
ANG-1170 |
Acute:
|
|
Chronic:
|
|
|
|
||
ANG-2864 (PARP inhibitor) |
Acute Liver Failure |
|
Ischemic injuries |
|
|
|
||
ANG-1122 (TGFβ antagonists) |
Fibrosis |
|
Market Opportunities
The size of target markets for Angion’s compounds is summarized in the following tables.
US market size for HGF/SF mimetics
| Disease | Indication | Prevalence | Incidence |
Cardiovascular disease |
Myocardial infarction |
|
2,000,000(1) |
Atherosclerosis |
5,100,000 |
|
|
Liver fibrosis |
Fibrosis secondary to HCV Chronic infection |
4,000,000 |
|
Kidney injury |
Contrast medium nephropathy |
|
2,000,000(1) |
Spinal cord injury |
Contusive spinal cord injury |
250,000 |
12,000 |
Fulminant liver failure |
Fulminant liver failure |
|
1,000 |
Lung fibrosis |
Idiopathic lung fibrosis, drug-induced fibrosis |
200,000 |
|
(1) The patient population with myocardial infarction undergoing angiography is at risk for contrast medium nephropathy
